z-bio 2025-07-03 3038

　　In the highly competitive field of top medical journals, 2020 welcomes a strong new member - Med.

As a strategic layout for Cell Press to enter the top medical journal market, Med has focused on publishing clinical and translational research with wide influence and change potential since its inception, aiming to accelerate the transformation of laboratory discovery into clinical applications.

Basic journal information

　　Journal official website: https://www.sciencedirect.com/journal/med/issues

　　ISSN: 2666-6340

　　Layout fee: US$9350

　　Early warning record: None

　　Self-induced quotient rate: 0.8%

　　Med is a medical flagship monthly magazine founded by Cell Press, an international top academic publishing group, in 2020.

　　The journal Med is committed to becoming a core platform for clinicians, translational researchers, biotechnology and pharmaceutical scientists to exchange knowledge, new ideas and leadership, with the aim of publishing research that can have an immediate impact on clinical treatment, promoting the boundaries of medical knowledge, and ultimately improving patient diagnosis and treatment.

　　The current editor-in-chief is Professor Duc Le, who received a PhD in Immunology and Microbiology from the Royal Holloway University in London and completed postdoctoral research, with rich academic publishing experience. Prior to joining Cell Press, he was the editor-in-chief of Lancet's eBioMedicine, and served as senior executive editor of The Lancet from January 2019 to September 2023.

　　01

　　Article fields and types

　　The core of Med lies in clinical research and translational research:

　　Clinical research: Special emphasis is placed on large-scale, rigorous design, and clear clinical significance in clinical trials (from Phase I to Phase IV, especially key Phase III trials), high-quality observational research, epidemiological research, precision medical research, etc.

　　Translational research: Focus on publishing results that quickly and effectively transform basic scientific discoveries into clinical applications, including disease mechanism research (need to have clear clinical relevance), the development and verification of new diagnostic and treatment methods (drugs, devices, diagnostic technologies), biomarker discovery and application, etc.

　　Article type: research papers, short reports/communications, comments, reviews, etc.

　　02

　　Influencing factors and partitions

　　As a new issue, Med has a strong development momentum. The first impact factor released in June 2022 was 17.0. It decreased slightly in 2023, with an impact factor of 12.8.

　　JCR partition Q1, ranking 5/189 (97.6%) in medical research and experimental partitions. It is worth noting that it was obtained for the first time in the Chinese Academy of Sciences this year and was shown to be a TOP journal in the first district of medicine.

　　03

　　Posting status

　　The number of publications in the first year after the journal was founded was relatively small, and the number of publications in the next two years was about 100, which decreased in 2022 to 113 and 88 in 2023.

　　Among them, Chinese scholars published a total of 53 articles in the journal, ranking second. Data from the past three years shows that Chinese scholars are only ranked fifth.

　　04

　　Review cycle and layout fee

　　Regarding the review speed of MED journals, the official website shows that the average time for the first decision (first review) to make the submission is only 3 days, and the average total time required for submission to be accepted is about 107 days (about 3.5 months). The journal is relatively efficient in processing processes, but this is the "average" time, and the processing time for specific manuscripts may be shorter or longer.

　　As a mixed journal, the traditional model does not require payment of layout fees. The layout fee published by OA is US$9,350, which is approximately RMB 67,300. For a journal with a score of nearly 13, this page is a bit expensive. Given that it ranks fifth in its field and is not too expensive, the big guys with sufficient funding can make it!

　　05

　　Submission experience

　　Netizen 1:

　　Review speed: 2.0 | Submission hit rate: 50.0

　　Focused research directions: stem cells; regenerative medicine; medical synthesis

　　The receiving field is very wide, positioned in translational medicine. It is not too life science (basic) like Cell, nor too clinical like Lancet. Med should be between the two, at the level of translational medicine. Although competition is fierce in similar journals, it is easy to enjoy the cool under the big tree. Don’t miss this future potential stock

　　Netizens said that there was no movement in the submission for half a month

　　Some paper submission status becomes under review after three days of submission.

　　Currently, netizens don’t have much experience in submissions, so you can wait and see.

　　Summarize

　　Although Med is a very young journal, it has the potential for top journals and has great potential for top journals and has a clear positioning of accurately focusing on clinical and translational research, and its unique mission of advocating the "unity of academics-clinical-industry-policy" to accelerate ethical transformation.

　　Before submitting, be sure to carefully study its detailed author guidelines and submission requirements to ensure that the manuscript meets its strict standards in terms of innovation, quality and standardization.